🔎 Trials Near Me

ホーム › 大うつ病性障害 › マサチューセッツ州 › Boston

Boston、MAにおける大うつ病性障害の臨床試験

Bostonとその周辺地域(約30マイル以内)の拠点で、大うつ病性障害に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト(英語)

ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

被験者募集中第3相
  • Adams Clinical Boston, Boston
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07775300

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

被験者募集中第3相
  • Adams Clinical Boston, Boston
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07573176

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

被験者募集中第3相
  • Boston Childrens Hospital, Boston
12歳〜17歳 · 全性別 · 2026/09/25更新 · NCT07227454

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

被験者募集中第3相
  • Adams Clinical Boston, Boston
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06793397

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

被験者募集中第3相
  • Vanda Investigational Site, Boston
18歳〜65歳 · 全性別 · 2026/09/24更新 · NCT06830044

Accelerated TMS for Perinatal Depression

被験者募集中
  • Brigham and Women's Hospital, Boston
18歳〜55歳 · 女性 · 2026/09/18更新 · NCT06968390

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

被験者募集中第2相
  • Seaport Investigator Site, Boston
18歳〜65歳 · 全性別 · 2026/09/14更新 · NCT07065240

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

被験者募集中第3相
  • Adams Clinical Boston, Boston
18歳〜74歳 · 全性別 · 2026/09/08更新 · NCT07076407

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

被験者募集中第2相
  • Draig Clinical Site, Boston
18歳〜75歳 · 全性別 · 2026/09/02更新 · NCT07610473

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

被験者募集中
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
22歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06423430

Home-Based tDCS Treatment Of Major Depressive Disorder

被験者募集中
  • Curavit Clinical Research (virtual study site), Boston
22歳〜70歳 · 全性別 · 2026/08/14更新 · NCT06976697

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

被験者募集中第3相
  • Athinoula A. Martinos Center for Biomedical Imaging, Charlestown · 1マイル先
18歳〜55歳 · 全性別 · 2026/08/13更新 · NCT06247839

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

被験者募集中第3相
  • Adams Clinical Boston, Boston
  • Adams Clinical Watertown, Boston
18歳〜74歳 · 全性別 · 2026/08/10更新 · NCT07592689

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

被験者募集中第3相
  • Adams Clinical Boston, Boston
18歳〜75歳 · 全性別 · 2026/08/06更新 · NCT07412756

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

被験者募集中第3相
  • Boston Clinical Trials Llc, Boston
18歳〜74歳 · 全性別 · 2026/08/03更新 · NCT06775379

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

被験者募集中第3相
  • Neurocrine Clinical Site, Boston
18歳以上 · 全性別 · 2026/07/24更新 · NCT06966401

Triage Survey for Psychiatry Research Eligibility

被験者募集中観察研究
  • Adams Clinical, Boston, Boston
18歳以上 · 全性別 · 2026/05/20更新 · NCT05800925

Mechanisms Of Orbitofrontal Stimulation in Depression

被験者募集中
  • Beth Israel Deaconess Medical Center, Boston
18歳〜65歳 · 全性別 · 2026/05/14更新 · NCT07230990

Mindfulness-Based fMRI Neurofeedback for Depression

被験者募集中
  • Northeastern University, Boston
13歳〜18歳 · 全性別 · 2026/04/29更新 · NCT05617495

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

被験者募集中第3相健康なボランティア歓迎
  • Lindus Health (Virtual Study Site), Boston
18歳以上 · 全性別 · 2026/04/29更新 · NCT07280065

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

被験者募集中観察研究
  • Beth Israel Deaconess Medical Center, Boston
18歳〜40歳 · 全性別 · 2026/03/10更新 · NCT06740383

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

被験者募集中
  • Harvard Medical School, Boston
18歳〜65歳 · 全性別 · 2026/02/05更新 · NCT05573074

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

被験者募集中第2相
  • Autobahn Site #137, Boston
18歳〜65歳 · 全性別 · 2026/01/20更新 · NCT06633016

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

被験者募集中第4相
  • Massachusetts General Hospital, Boston
18歳〜70歳 · 全性別 · 2025/12/12更新 · NCT05450432

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

被験者募集中第3相
  • Neurocrine Clinical Site, Boston
18歳以上 · 全性別 · 2025/10/29更新 · NCT06786624

Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

被験者募集中健康なボランティア歓迎
  • Massachusetts General Hospital, Boston
18歳〜65歳 · 全性別 · 2025/09/29更新 · NCT05523817

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

被験者募集中第2相
  • Massachusetts General Hospital, Boston
18歳〜85歳 · 全性別 · 2025/09/12更新 · NCT05570812

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

被験者募集中健康なボランティア歓迎
  • Massachusetts General Hospital, Boston
18歳〜65歳 · 全性別 · 2025/09/10更新 · NCT04296604

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

被験者募集中第2相
  • Massachusetts General Hospital, Boston
25歳〜50歳 · 全性別 · 2025/05/07更新 · NCT06136546

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

被験者募集中第4相
  • Clinical Research Site, Boston
18歳〜65歳 · 全性別 · 2025/01/23更新 · NCT06223880

Peripheral Neuroimmune Mechanisms of Hyperthermia

被験者募集中
  • Massachusetts General Hospital Depression Clinical & Research Program, Boston
18歳〜65歳 · 全性別 · 2023/03/10更新 · NCT05366270

他の都市における大うつ病性障害の試験

Bostonにおける他の研究

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。